Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "DKN-01 Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering. "DKN-01 Market Size, Forecast, ...
Leap Therapeutics Inc (NASDAQ: LPTX) will present updated data from the DisTinGuish Phase 2a study of DKN-01, in combination with tislelizumab in gastric or gastric gastroesophageal junction cancer (G ...
Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma Patients had ...
- High Levels of Tumoral DKK1 Expression Correlated with Improved Clinical Outcomes in Heterogenous Esophagogastric Cancer Patients Treated with DKN-01 as a Monotherapy or in Combination - DKK1-high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results